Guggenheim downgraded Outlook Therapeutics (OTLK) to Neutral from Buy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- Outlook Therapeutics’ resubmission for wet AMD candidate rejected by FDA
- Navigating Trade Turbulence: Outlook Therapeutics’ Struggle with Global Trade Policies
- Outlook Therapeutics Reports Q3 2025 Earnings and Milestones
- Outlook Therapeutics reports Q3 adjusted EPS (44c) vs. (83c) last year
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?